These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 17662875)

  • 1. Inflammatory bowel disease.
    Stocco G; Decorti G; Bartoli F; Martelossi S; Ventura A
    Lancet; 2007 Jul; 370(9584):316-7. PubMed ID: 17662875
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacogenomics and IBD: TPMT and thiopurines.
    Sandborn WJ
    Inflamm Bowel Dis; 2004 Feb; 10 Suppl 1():S35-7. PubMed ID: 15168829
    [No Abstract]   [Full Text] [Related]  

  • 3. [Therapy of chronic inflammatory bowel diseases with azathioprine, 6-mercaptopurine and 6-thioguanine. Clinico-pharmacologic aspects].
    Schwab M; Herrlinger K; Schaeffeler E; Stange EF
    Dtsch Med Wochenschr; 2003 Feb; 128(8):378-85. PubMed ID: 12594624
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacogenomics in the treatment of inflammatory bowel disease.
    Smith MA; Marinaki AM; Sanderson JD
    Pharmacogenomics; 2010 Mar; 11(3):421-37. PubMed ID: 20235796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring of azathioprine/6-mercaptopurine treatment in children with IBD is not necessary.
    Griffiths AM
    Inflamm Bowel Dis; 2003 Nov; 9(6):389-91; discussion 392-3. PubMed ID: 14671489
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease.
    Winter J; Walker A; Shapiro D; Gaffney D; Spooner RJ; Mills PR
    Aliment Pharmacol Ther; 2004 Sep; 20(6):593-9. PubMed ID: 15352906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics of inflammatory bowel disease.
    Katsanos KH; Papadakis KA
    Pharmacogenomics; 2014 Dec; 15(16):2049-62. PubMed ID: 25521361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring of AZA/6-MP treatment in children with IBD is necessary.
    Dubinsky MC
    Inflamm Bowel Dis; 2003 Nov; 9(6):386-8; discussion 392-3. PubMed ID: 14671488
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacogenetics of thiopurine therapy in paediatric IBD patients.
    De Ridder L; Van Dieren JM; Van Deventer HJ; Stokkers PC; Van der Woude JC; Van Vuuren AJ; Benninga MA; Escher JC; Hommes DW
    Aliment Pharmacol Ther; 2006 Apr; 23(8):1137-41. PubMed ID: 16611274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of thiopurine methyltransferase genotype screening in IBD.
    Kitiyakara T; Hayat J; McIntyre AS
    Aliment Pharmacol Ther; 2005 Mar; 21(6):790-1; author reply 791-2. PubMed ID: 15771767
    [No Abstract]   [Full Text] [Related]  

  • 11. [Pharmacogenetic study of thiopurine S-methyltransferase (TPMT) and thiopurine toxicity].
    Corominas H; Díaz C; Vázquez G; Baiget M
    Rev Esp Enferm Dig; 2002 Oct; 94(10):635-6. PubMed ID: 12647415
    [No Abstract]   [Full Text] [Related]  

  • 12. Novel pharmacogenetic markers for treatment outcome in azathioprine-treated inflammatory bowel disease.
    Smith MA; Marinaki AM; Arenas M; Shobowale-Bakre M; Lewis CM; Ansari A; Duley J; Sanderson JD
    Aliment Pharmacol Ther; 2009 Aug; 30(4):375-84. PubMed ID: 19500084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease.
    Chouchana L; Narjoz C; Beaune P; Loriot MA; Roblin X
    Aliment Pharmacol Ther; 2012 Jan; 35(1):15-36. PubMed ID: 22050052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetics and inflammatory bowel disease: progress and prospects.
    Ho GT; Lees C; Satsangi J
    Inflamm Bowel Dis; 2004 Mar; 10(2):148-58. PubMed ID: 15168816
    [No Abstract]   [Full Text] [Related]  

  • 15. Thiopurine-S-methyltransferase genotype and the response to azathioprine in inflammatory bowel disease.
    Stocco G; Martelossi S; Decorti G; Bartoli F; Ventura A
    Aliment Pharmacol Ther; 2007 Oct; 26(7):1083-4; author reply 1084-5. PubMed ID: 17877516
    [No Abstract]   [Full Text] [Related]  

  • 16. Evidence for a functional genetic polymorphism of the Rho-GTPase Rac1. Implication in azathioprine response?
    Bourgine J; Garat A; Allorge D; Crunelle-Thibaut A; Lo-Guidice JM; Colombel JF; Broly F; Billaut-Laden I
    Pharmacogenet Genomics; 2011 Jun; 21(6):313-24. PubMed ID: 21372752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical use and practical application of TPMT enzyme and 6-mercaptopurine metabolite monitoring in IBD.
    Seidman EG
    Rev Gastroenterol Disord; 2003; 3 Suppl 1():S30-8. PubMed ID: 12684587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Should thiopurine methyltransferase genotypes and phenotypes be measured before thiopurine therapy in patients with inflammatory bowel disease?
    Fangbin Z; Xiang G; Minhu C; Liang D; Feng X; Min H; Pinjin H
    Ther Drug Monit; 2012 Dec; 34(6):695-701. PubMed ID: 23149442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Azathioprine in inflammatory bowel disease: improved molecular insights and resulting clinical implications.
    Atreya I; Neurath MF
    Expert Rev Gastroenterol Hepatol; 2008 Feb; 2(1):23-34. PubMed ID: 19072367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do ITPA and TPMT genotypes predict the development of side effects to AZA?
    Duley JA; Marinaki AM; Arenas M; Florin TH
    Gut; 2006 Jul; 55(7):1048; author reply 1048-9. PubMed ID: 16766757
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.